Cytogenetic Studies on Two Drugs for Natural Relief of Prostatic Disorders

Abstract

Pepon and prostoplex, new drugs containing natural substances, are used in the treatment of prostatic disorders. The cytogenetic effects of these drugs were tested in mice's bone marrow and spermatocytes cells at two doses comparable to propose human therapeutic and double therapeutic doses.
The results revealed that the total numbers of structural chromosomal aberrations in mice's bone marrow, with or without gap, were significantly increased at p<0.01 for pepon and at p<0.05 for prostoplex at therapeutic doses. Whereas at double therapeutic doses, the two drugs showed highly significant increases in the total numbers of structural chromosomal aberrations compared with controls.
The frequency of total chromosomal aberrations in mice's spermatocytes was increased at significant level p<0.01 for both drugs at therapeutic doses. At double therapeutic doses, pepon and postoplex increased the total chromosomal aberrations in spermatocyte cells at highly significant level p<0.001.
In conclusion, the cytogenetic analysis of pepon and prostoplex revealed that the two drugs have adverse effect on somatic and germinal materials at therapeutic dose. Also, our results are considered as a caution for the treatment with these two drugs at double therapeutic doses, which have mutagenic effect on somatic and germinal materials.